Stockwinners Market Radar for October 17, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment buys 467K shares of Cerus today

19:50 EDT S&W Seed trading halted, news pending

19:50 EDT Kintara Therapeutics Inc trading halted, news pending

19:06 EDT TD Synnex director sells $2.4M in common stock - In a regulatory filing, TD Synnex disclosed that its director Richard Hume sold 20K shares of common stock on October 16th in a total transaction size of $2.4M.

18:15 EDT Meta Platforms CLO Newstead sells 905 class A shares - In a regulatory filing, Meta Platforms chief legal officer Jennifer Newstead disclosed the sale of 905 class A common shares of the company on October 15 at a price of $589.97 per share.

17:53 EDT Sam Altman's Worldcoin rebrands to 'World,' unveils iris-scanning Orb - In an earlier post to its blog, Sam Altman co-founded cryptocurrency ventureWorldcoin said in part: "AI is progressing faster than even many experts expected. To help bring World ID access to the millions of people who haven't yet had a chance to verify at an Orb, World ID 3.0 introduces World ID Credentials, a new way to enable the World Network to scale and add utility even faster. Starting today in the US, Malaysia and the UK and expanding in the coming weeks to many more countries around the world, World ID holders can now optionally store information from their physical NFC-enabled passports in World App on their device-with none of the data stored off their device or accessible to World Foundation, TFH or any third party-then use their World ID to prove things like age, nationality and unique passport ownership without revealing their real identity. In addition, the World Foundation has decided to allow Verified Passport holders to claim WLD tokens (where available) even before they fully Orb-verify their World ID."... Publicly traded companies in the cryptocurrency space include Bit Digital (BTBT), Coinbase (COIN), Mara Holdings (MARA), MicroStrategy (MSTR), Riot Platforms,(RIOT) Stronghold Digital Mining (SDIG) and TeraWulf (WULF) Bitcoin Investment Trust (GBTC), BTC, $BTC, BITCOIN, $ETH, $LTC.. Reference Link

17:38 EDT Comtech announces transformation strategy and capital structure update - Comtech's Board of Directors and management team are executing a strategy to transform Comtech into a pure-play satellite and space communications company and provided a capital structure update. Ongoing and future actions supporting Comtech's transformation strategy include: an exploration of strategic alternatives for the company's Terrestrial & Wireless Networks segment, which is well underway; the pursuit of further portfolio-shaping opportunities to enhance profitability, efficiency and focus; and the implementation of additional operational initiatives to align Comtech's go-forward cost structure with a pure-play focus on satellite and space communications. Comtech's T&W business is a provider of 911 infrastructure and solutions for state and local governments and telecom carriers across North America. The Board in recent months commenced a strategic alternatives process for the T&W business. There is no timeframe for the conclusion of the process. Comtech's Satellite & Space Communications segment is a U.S.-based provider of advanced modems and high-power amplifier technologies. Proceeds from the potential divestiture of T&W would enable Comtech to substantially simplify its capital structure and strengthen its balance sheet. The company has undertaken a detailed evaluation of its S&S portfolio to identify opportunities to divest, separate and/or rationalize businesses or facilities that are not core to Comtech's go-forward focus. In its Q4, Comtech made the decision to exit its subsidiary operations in Basingstoke, U.K. Comtech expects to realize approximately $10M of annual cash savings. Comtech has conducted a review of its product portfolio to focus future investment on the company's most strategic, high-margin revenue opportunities within its S&S portfolio. The company anticipates reporting significantly lower-than-expected performance, primarily in its S&S segment, in Q4.

17:12 EDT Netflix says approach towards pricing 'remarkably consistent' for years

17:11 EDT Netflix says not changing talent compensation structure - Says compensation structure benefits creators. Says open to more "bespoke" deals with talent on a case-by-case basis.

17:08 EDT Intuitive Surgical raises FY24 procedure growth view to 16%-17% from 15.5%-17% - Backs FY24 gross profit margin view 68.5%-69% of net revenue. Narrows FY24 operating expense growth view to 10%-12% from 10%-13%. Backs FY24 capital expenditures view $1B-$1.2B. Narrows FY24 tax rate view to 22%-23% from 22%-24%. Says increasing headwinds in Asia. Says has seen strong average selling price performance in Korea. Says encouraged by broad use of DaVinci 5. Says placements in U.S. will progressively shift towards trade ins. Says UK placements challenged by ongoing government measures impacting healthcare spending. Says leasing represented 58% of placements. Comments and guidance taken from Q3 earnings conference call.

16:59 EDT Netflix 'feels great' about margin growth for 2024 - Says service seeing "consistent" stream of quality content from international creators. Says "feels great" about margin growth for 2024. Says underlying business trends in Latin America are "healthy." Says ads plan tier remains "healthy." Comments taken from Q3 earnings conference call.

16:51 EDT Western Alliance reports Q3 net interest margin 3.61% vs. 3.67% last year - Provision for credit losses totaled $33.6M for the third quarter 2024, compared to $37.1M for the second quarter 2024, and $12.1M for the third quarter 2023.

16:32 EDT Lincoln Electric raises quarterly dividend by 5.6% to 75c per share - The dividend is payable January 15, 2025, to shareholders of record at the close of business on December 31, 2024. "Our dividend increase reflects strong cash flow generation of the business, solid execution of our Higher Standard 2025 Strategy, and confidence in our ability to continue to deliver superior long-term value for our shareholders through the cycle," stated Steven B. Hedlund, CEO.

16:31 EDT Greystone Housing and BIO in JV for loan investments to aid affordable housing - Greystone Housing Impact Investors announced the formation of a joint venture with BlackRock Impact Opportunities BIO to invest in loans which will finance the construction and/or rehabilitation of affordable multifamily housing properties across the US...Brian Mwarania, Senior Investor for BlackRock Impact Opportunities said, "We are proud to partner with Greystone Housing Impact Investors LP. Our new Joint Venture aims to address the acute shortage of high-quality affordable housing across the US through innovative construction financing solutions. We look forward to working closely with the Partnership to structure compelling investments that achieve our clients' social impact objectives."

16:27 EDT South Plains Financial boosts dividend 7% to 15c per share - South Plains Financial announced that its Board of Directors has declared a quarterly cash dividend of 15c per share of common stock, a 7% increase from the most recent quarterly cash dividend declared in July 2024. The dividend is payable on November 12 to shareholders of record as of the close of business on October 28.

16:22 EDT Fluor JV receives notice to proceed on Hanford integrated tank contract - Fluor Corporation announced that the U.S. Department of Energy has approved Hanford Tank Waste Operations & Closure, LLC - a joint venture led by a subsidiary of BWX Technologies, Inc., with Fluor and Amentum - to begin the Hanford Integrated Tank Disposition Contract. The contract has an estimated ceiling of $45B over a 10-year ordering period for environmental management operations at the Hanford Site in Washington state. Fluor will recognize its share of earnings from this new contract using the equity method of accounting beginning in the fourth quarter of 2024. "Fluor and our H2C partners are ready to get to work on this important DOE cleanup mission," said Tom D'Agostino, Group President of Fluor's Mission Solutions business. "We've been a proud member of the Tri-Cities community for more than 25 years, beginning with the Project Hanford Management Contract in 1996 and continuing through to our role today on the Central Plateau Cleanup Contract. We look forward to supporting the DOE and other site contractors in continuing our effort and in working with the community."

16:19 EDT Fresh2 Group gets Nasdaq staff delisting determination, to request hearing - Fresh2 Group announced that on October 16 it received a Staff Determination Letter from the Nasdaq Stock Market indicating that the Company did not comply with Nasdaq's filing requirements as set forth in Listing Rule 5250(c)(1). The letter is a result of the Company's failure to file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, and June 30, within the required deadlines. Nasdaq had previously granted the Company an exception until September 27, 2024, to regain compliance. Nasdaq has determined that the Company has not met the terms of the exception, as the Company has yet to file the necessary reports. Fresh2 intends to timely request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, to stay the suspension of the Company's securities for 15 days from the date of the hearing request. The Company also plans to request a stay of the suspension pending the hearing. The Company intends to present a plan to achieve and sustain compliance for continued listing and to request an extension of time within which to complete its compliance plan. However, there can be no assurance that the Panel will grant the Company's request for a further extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.

16:18 EDT Supernus announces data from SPN-820 study - Supernus Pharmaceuticals announced data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder. The study examined the safety and tolerability of SPN-820 2400 mg given once every three days as an adjunctive treatment to the current baseline antidepressant therapy, as well as assessed the rapid onset of improvement in depressive symptoms. The analysis is based on 40 enrolled subjects, of which 38 completed the 10-day treatment period. Clinically meaningful improvement of -6.1 at two hours and -9.6 at Day 10 on the Hamilton Depression Rating Scale-6 Items, or HAM-D6, total score. Clinically meaningful improvement of -16.6 at four hours and -22.9 at Day 10 on the Montgomery Asberg Depression Rating Scale, or MADRS, total score. Suicidal ideation decreased by 80%. SPN-820 was well-tolerated with few adverse events, or AEs, and had acceptable tolerability with a discontinuation rate of 2.5% due to AEs. Most common AEs related to the drug included headache, nausea, somnolence, and dizziness. Additional AEs such as cognitive disorder, dry mouth, fatigue, nasal decongestion, and paresthesia oral were observed.

16:13 EDT Aura Biosciences announces early data from bel-sar trial - Aura Biosciences announced early data from an ongoing Phase 1 clinical trial of bel-sar in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone and bel-sar with light activation. The secondary endpoints are to evaluate biological activity and immune mediated changes in the tumor microenvironment, or TME. Ten of 13 study participants had low grade disease, approximating the 70% incidence of this patient population among all NMIBC patients. The other three study participants had high grade disease. In patients receiving bel-sar with light activation, 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation. Two out of 3 patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy. Aura will host a Virtual Urologic Oncology Investor Event at 4:30 pm ET. The ongoing Phase 1 trial is a two-part, open-label clinical trial, designed to assess the safety and feasibility of bel-sar as a monotherapy. The study treatment is administered 7 to 12 days before the scheduled transurethral resection of bladder tumor, or TURBT, the standard of care procedure. The participants are followed for safety monitoring over a 56-day period. The trial is also evaluating bel-sar's biological activity with histopathological evaluation of tissue samples collected at the time of TURBT with evaluation of focal necrosis and immune changes in the tumor microenvironment. Part 1 of the trial is complete, with patients receiving a single bel-sar dose without light activation. Part 2 of the trial is ongoing. Eight patients with a confirmed tumor at time of treatment have received either 100ug or 200ug of bel-sar as a single dose. Of these eight patients, five had low grade disease and three had high grade disease. Seven of these eight patients had a history of recurrent bladder cancer and had undergone multiple TURBTs and adjuvant treatments such as Bacillus Calmette-Guerin, mitomycin, gemcitabine, cetrelimab and tamoxifen prior to trial enrollment. In the Phase 1 trial expansion, Aura plans to test additional doses and treatment regimens. In the safety analysis as of the September 9 data cut-off date, bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported. No serious adverse events have been reported. No significant differences between the light-activated and non-light activated cohorts have been observed. The data in these 8 patients receiving bel-sar with light activation showed clinical activity detectable as soon as 7 days after a single low dose of bel-sar with light activation. This was demonstrated by histopathological evidence of clinical complete response, necrosis, immune activation or visual tumor shrinkage observed on cystoscopy. For this analysis, "clinical complete response" was defined as the absence of tumor cells on histopathologic evaluation. Of the patients with low-grade disease, 4 out of 5 exhibited a clinical complete response, with no tumor cells detected in histopathological evaluation post-treatment in the target and in several non-target bladder tumors. Two of 3 of the patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy, while tumor cells were still present on histopathological evaluation. Immune activation was noted in all patients in both treated target and untreated non-target bladder tumors with infiltration of effector CD8+ and CD4+ T-cells. This data provides evidence of a bladder urothelial field effect with a single low dose of bel-sar with light activation, potentially indicating a broader immune response in the bladder beyond the target tumor in these patients.

16:10 EDT WD-40 down 2% at $260 after Q4 results and FY25 guide

16:08 EDT ABM appoints Miranda Tolar as general counsel - ABM announced the appointment of Miranda Tolar as executive VP and general counsel effective January 1, 2025. In this role for the company, Tolar will oversee the legal, compliance, risk and safety organization, succeeding Andrea Newborn who recently announced her retirement. Newborn will remain with the company through a transition period ending in February 2025. First joining ABM in 2011, Tolar most recently served as senior VP and deputy general counsel overseeing litigation and employment law.

16:06 EDT UTime receives noncompliance notification from Nasdaq - UTime announced that on October 10, the company received a notification letter from the Nasdaq Listing Qualifications Staff of Nasdaq notifying the company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).

16:03 EDT Docebo partners with Intercap on free e-learning platform - The company states: "As part of the company's ongoing commitment to Corporate Social Responsibility, Docebo has teamed up with Intercap Impact, a division of Intercap Equity Inc. to create OWL - Open World Learning Inc. - a free e-learning platform designed for small Canadian and US charities and nonprofits. This partnership will remove the cost barrier associated with e-learning, a challenge many smaller charities and nonprofit organizations face. Using OWL, powered by Docebo, eligible organizations will now be able to build stronger teams and empower staff, volunteers, and board members with essential e-learning in key areas, including HR Compliance, DEI, Mental Health, Board Governance, Leadership, professional development, and more."

16:03 EDT Netflix sees Q4 paid net additions higher than in Q3 - Netflix said in its quarterly letter to investors: "We expect paid net additions to be higher in Q4 than in Q3'24 due to normal seasonality and a strong content slate. We project Q4 operating margin of 22%, a five percentage point year-over-year improvement."

16:00 EDT Getac selects Veritone Redact for body-worn camera solutions - Veritone announced that Getac Technology Corporation, a player in rugged computing devices and mobile video solutions, will offer its customers Veritone Redact, an AI-powered software designed to streamline the redaction process for body-worn cameras, in-car video, interview rooms and transport camera footage. The integration of Veritone Redact into Getac's Evidence Management System will provide law enforcement agencies with an advanced tool for managing video evidence while ensuring compliance with privacy regulations. "We are proud to partner with Veritone and offer advanced redaction to our customers," said Mike McMahon, President of Getac North America. "Mobile video and video evidence are a critical tool for law enforcement agencies and, with Veritone Redact, we can now offer an integrated solution that ensures both transparency and compliance, while significantly reducing the time spent on video processing."

15:21 EDT FDA discloses summary of violations at Humacyte's Durham, NC facility - The U.S. Food and Drug Administration disclosed in a form 483 summary a number of violations found at Humacyte's Durham, North Carolina facility. According to an inspection performed earlier thtis year, quality oversight at the facility is "inadequate" for a number of issues, including: the existence of 10 out of 31 out-of-specification investigations that were open for more than 100 days, with the longest being open for 710 days; the contract cleaning crew not being current with their cGMP Refresher Training as required by the Training Program, with one member of the cleaning crew not current on the GxP Cleaning Contractor Core Trainign "Facility Cleaning and Disinfection"; a lack of a complete record for the role-based training for an operator, and; the quality review of the preventative maintenance of the air handling unit being approved without the required documentation. Reference Link

14:01 EDT Amazon says 'Election Night Live with Brian Williams' to stream on Prime Video - Amazon Prime Video and White Cherry Entertainment announced "Election Night Live with Brian Williams," a one-night special delivering election results and analysis to Amazon customers on November 5, 2024, beginning at 5 p.m. ET/ 2 p.m. PT. The program will be produced by Glenn Weiss and Ricky Kirshner with Jonathan Wald as executive producer and showrunner, and Weiss also serving as director. Brian Williams will be joined live by guests including prominent contributors across news and traditional media, representing a range of backgrounds and perspectives, to share real-time poll results and commentary while also referencing third-party news sources across all political affiliations. "Election Night Live with Brian Williams" will meet global viewers where they are, providing a unique, first-stop opportunity to follow the evening's results in an informative, accessible and non-partisan presentation directly on Prime Video, the company said. Guests will be announced in the coming weeks. "After 41 years in the business-from local news to network shows to cable news-this feels like the next big thing. And the global marketplace of Amazon is a natural home for this first-of-its-kind venture," said Brian Williams. "Together we will follow the storyline on election night wherever it leads us." Reference Link

13:47 EDT ALK-Abello announces FDA clearance of AccuTest testing devices (Oct. 7) - On October 7, ALK announced the licensing of a new line of ALK branded allergy skin testing devices and well trays. This new line includes the AccuTest-1, AccuTest-8 and AccuTest-10 Allergy Skin Testing Devices for allergy testing and diagnosis as well as the AccuTest 48-well and 60-well allergen trays. The new line consists of the single skin prick testing device, AccuTest-1, and the multi-head AccuTest-8 and the AccuTest-10. The multi-head applicators are 8-head and 10-head models, respectively, and are designed with enhanced ergonomics, like larger top surface area and ribbed grip, for more uniform pressure leading to more consistent and reliable results. Both single prick and multi-head devices feature smaller tine lengths and diameters, to increase accuracy and minimize discomfort to the patient, the company stated.

13:05 EDT DaVita appoints Jessica Hergenreter as CPO - DaVita announced Jessica Hergenreter as its new chief people officer. In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates worldwide. Before joining DaVita, Hergenreter spent 13 years at Vail Resorts, where she excelled in various leadership roles, from HR business partner to Chief of Staff to the CEO.

12:11 EDT Nektar says published Phase 1 NKTR-25 data show favorable efficacy - Nektar Therapeutics announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia in Blood, the peer-reviewed medical journal of the American Society of Hematology. NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors. The data published in Blood showed favorable efficacy with eight out of nine patients whom successfully received CAR19-22 followed by NKTR-255 achieving measurable residual disease negative remission, the company said in a statement. The study further demonstrated that, at 12 months, relapse-free/progression-free survival for NKTR-255 in combination with the CD19-22 CAR-T cell therapy was double that of historical controls - 67% versus 38%, Nektar added.

12:01 EDT Select Medical, SSM form JV partnership to operate inpatient rehab hospital - Select Medical Corporation and SSM Health announced the formation of a joint venture partnership to own and operate a 50-bed inpatient rehabilitation hospital in Oklahoma City to be named SSM Health Rehabilitation Hospital - Oklahoma City. The hospital will operate at 700 NW 7th Street and incorporate SSM Health's 12-bed acute rehabilitation unit presently located in St. Anthony Hospital in Oklahoma City. SSM Health Rehabilitation Hospital - Oklahoma City is scheduled to open in December 2024. Under a separate joint venture agreement formed in 2009, Select Medical and SSM Health operate three inpatient rehabilitation hospitals in Missouri located in Richmond Heights, Lake St. Louis and Bridgeton. The partnership also includes 79 outpatient physical therapy centers and 10 rehabilitation day institutes throughout the St. Louis region. Select Medical will serve as majority owner and managing partner of the new joint venture.

12:00 EDT Elevance Health falls -12.2% - Elevance Health is down -12.2%, or -$60.78 to $436.18.

12:00 EDT Webster Financial rises 11.0% - Webster Financial is up 11.0%, or $5.37 to $53.99.

12:00 EDT NexGen Energy rises 89.7% - NexGen Energy is up 89.7%, or $3.87 to $8.19.

11:39 EDT Ferrari unveils new F80 supercar - Ferrari unveiled the new F80 supercar, which will be produced in a limited run of just 799 examples and joins the pantheon of icons such as the GTO, F40 and LaFerrari by showcasing the best that the Maranello-based marque has achieved in terms of technology and performance. "The latest addition to this family, the F80, is tasked with embodying the ultimate in engineering for an internal-combustion-engined vehicle and employs all the most advanced technological solutions, including latest-generation hybrid technology for the powertrain, to achieve unparalleled levels of power and torque," the company said. "Every aspect of the architecture is conceived to maximise performance, from the carbon-fibre chassis and extreme aerodynamic solutions far beyond anything seen before in a road-legal car, to the new active suspension optimised to let the driver wring every ounce of performance from the car on the track." Reference Link

11:27 EDT Campbell, Harris Blitzer Sports & Entertainment enter marketing partnership - Harris Blitzer Sports & Entertainment and Campbell Soup Company announced a unique marketing partnership spanning four storied sports franchises across several of the world's biggest leagues. Campbell's will serve as an official partner to the Philadelphia 76ers, the Washington Commanders, New Jersey Devils, Prudential Center in Newark, N.J., and Joe Gibbs Racing. The multi-year partnership will enable fans to connect and engage with Campbell's leading portfolio of brands through unique activations and authentic offerings in prominent sports and entertainment markets.

11:12 EDT Expedia appoints Ramana Thumu as CTO - Expedia Group announced the appointment of Ramana Thumu as the company's Chief Technology Officer. Ramana will lead Expedia Group's technology organization, overseeing engineering, data, artificial intelligence, cloud platforms, and security, while capitalizing on the company's tech and platform investments in recent years. Ramana joins Expedia Group from Fanatics Commerce, where he most recently served as Chief Product and Technology Officer.

11:04 EDT Southwest enters sustainable aviation fuel supply agreement with Valero - Southwest Airlines (LUV) announced a sustainable aviation fuel supply agreement with Valero Marketing and Supply Company, a subsidiary of Valero Energy Corporation (VLO), to bring SAF to Chicago Midway International Airport in the state's largest announced SAF supply agreement. As part of the two-year agreement, Southwest will purchase a minimum of 3.6 million gallons of neat SAF for use in its operations as early as Q4 2024, with the option to purchase up to 25 million gallons of neat SAF over the agreement's term. On a blended basis, this would represent up to 35% of Southwest's jet fuel out of MDW based on the carrier's usage in the last year.

10:52 EDT Pineapple Energy Inc trading resumes

10:34 EDT Focus Impact Acquisition Corp trading halted, volatility trading pause

10:28 EDT Affirm falls after Apple adds Klarna payment options to iOS 18 - Shares of Affirm (AFRM) are moving lower after Apple (AAPL) said that with iOS 18, eligible users can now access installment loan options from Affirm in the U.S. and from Monzo Flex in the U.K. when checking out with Apple Pay online and in-app on iPhone and iPad. "And starting today, eligible users in the U.S. and U.K. will also have the option to access Klarna's flexible payment options right at checkout online and in-app with Apple Pay on iPhone and iPad," Apple added. Shares of Affirm are down 7% to $44.53 in early trading.

10:04 EDT Revolve Group names Jeon Somi as global brand ambassador - REVOLVE announces JEON SOMI, the multifaceted South Korean-Canadian K-Pop artist, as the brand's first-ever global brand ambassador. Known for her vibrant, playful style and cool girl energy, JEON SOMI effortlessly embodies the spirit of REVOLVE, where fashion meets individuality. JEON SOMI's approach to style and her unique blend of boldness and sophistication resonate with the REVOLVE aesthetic. Through this collaboration, she will merge music and fashion - bringing her energy to the REVOLVE audience while expanding the brand's presence globally and to an ever-growing Gen Z fanbase.

10:02 EDT Third Point discloses new position in DSV, touts Cinemark - In the firm's Q3 investor letter, a copy of which was seen by The Fly, Third Point stated: "During the Third Quarter, we initiated a new position in the Danish freight forwarder DSV. DSV has come a long way from its origins as a Nordic road-hauler to become the world's third largest freight forwarder, with a formidable track record of consolidating the fragmented global freight forwarding industry. We believe the company has an impressive culture that is systems-driven and returns-focused. DSV has generated an approximately 20% EPS CAGR over the past 10 years and is widely recognized as the best-in-class operator, with industryleading growth and profit margins. DSV emerged as the leading bidder in the auction of DB Schenker, a subsidiary of German state-owned Deutsche Bahn AG, and one of its largest competitors. DB Schenker is similar in size to DSV but only half as profitable. We believe the integration and synergy capture expected from this combination will follow a proven playbook and drive earnings accretion in excess of 30%." The firm also stated in the letter: "Earlier this year we took a stake in Cinemark, the third largest movie theater chain in the U.S. We believe Cinemark is poised for underappreciated growth over the next few years as the supply of theatrical releases rebounds from pandemic- and strike-related headwinds. In addition, we believe Cinemark will gain share from undercapitalized competitors... Given the significant recovery in box office, potential for continued share gain and high operating leverage of the business, we think Cinemark can generate over $4 of FCF/share in 2026, which is meaningfully higher than pre-pandemic levels and should grow in the following years."

10:00 EDT TSMC rises 9.6% - TSMC is up 9.6%, or $18.09 to $205.57.

10:00 EDT WNS Holdings falls -12.2% - WNS Holdings is down -12.2%, or -$6.04 to $43.65.

10:00 EDT Elevance Health falls -15.5% - Elevance Health is down -15.5%, or -$76.80 to $420.16.

09:48 EDT WNS Holdings falls -11.4% - WNS Holdings is down -11.4%, or -$5.66 to $44.03.

09:48 EDT Direxion Daily Semiconductor Bull 3X Shares rises 7.2% - Direxion Daily Semiconductor Bull 3X Shares is up 7.2%, or $2.48 to $36.94.

09:47 EDT NexGen Energy rises 87.4% - NexGen Energy is up 87.4%, or $3.77 to $8.10.

09:43 EDT Avadel Pharmaceuticals announces FDA approval of sNDA for LUMRYZ - Avadel Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its supplemental new drug application for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. LUMRYZ is a once-at-bedtime formulation extended-release sodium oxybate and was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS in adult patients with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population 7 years and older on October 16, 2024, and was granted Orphan Drug Exclusivity through October 16, 2031.

09:37 EDT Faraday Copper provdes exploration update on Copper Creek drill program - Faraday Copper provided an exploration update and announced the results of one drill hole from its ongoing Phase III drill program at the Copper Creek Project, located in Arizona. The hole was drilled to evaluate the near-surface mineralization above the recently discovered Banjo breccia in the American Eagle area. Paul Harbidge, President and CEO, commented "It is very exciting that this result further delineates the recently discovered Banjo breccia and now outlines 400 vertical metres of mineralization from the surface outcrop. The nature of mineralization in this hole suggests significant concentration of copper through supergene enrichment. To date, approximately 75% of our Phase III drilling has been focused on the discovery of additional near-surface mineralization outside the resource area to further unlock the potential scale of the project." Highlights: At the Banjo breccia, drill hole FCD-24-074 intersected 22.65 metres at 1.31% copper within 50.20 m at 0.74% copper from 46.20 m. This hole, together with previous drilling, and surface geological mapping demonstrates that mineralization at Banjo extends from surface to 400 m depth and remains open. Copper Creek boasts significant exploration upside with several new high priority targets being drill tested, including: The Rum area features porphyry-hosted copper oxide mineralization at surface and several breccias over an area of approximately 250 m by 400 m, located 700 m north of the resource area. The American Eagle area hosts numerous untested breccias with anomalous copper at surface and drilling is currently focused on further delineating mineralization and testing new breccia targets.

09:35 EDT Tevogen reports $1B revenue forecast for oncology pipeline in launch year - Tevogen Bio announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. "At Tevogen, we strive to turn our vision into reality ensuring our commitment translates into tangible results. Our priority is the well-being of cancer patients. With compelling evidence that SARS-CoV-2 remains a serious threat to those undergoing immunosuppressive treatments and chemotherapy, our first pivotal study with TVGN 489 is being designed specifically to help these vulnerable patients combat the infection," commented Sadiq Khan, Chief Commercial Officer.

09:27 EDT Tomi Environmental reports Q3 iHP corporate service revenue of $650,000 - TOMI Environmental Solutions announced that its iHP Corporate Service division is expected to recognize revenues of approximately $650,000 for the three month ended September 30, 2024. This marks a record for the division's quarterly performance, surpassing historical averages of approximately $250,000 per quarter or $1 million annually. TOMI intends to announce its full Q3 financial results, including total revenue for the third quarter on October 30th, 2024. The division's significant revenue growth in the third quarter reflects the rising demand for TOMI's iHP services, particularly within the life sciences sector. TOMI has effectively expanded its marketshare, strengthening its position as a leader in providing comprehensive solutions across a broad range of environments. As a result of ongoing strategic initiatives, the Company remains well positioned to further expand its footprint in the life sciences space.

09:22 EDT SentinelOne expands strategic deal with AWS on AI-powered cybersecurityAmazon.com - SentinelOne (S) announced an extension of its strategic collaboration agreement SCA with Amazon (AMZN) Web Services AWS , designed to deliver generative AI benefits. Under the terms of the agreement, SentinelOne's Purple AI cybersecurity analyst will be powered by Amazon Bedrock, to provide AI-powered security and protection for customers. Additionally, the expanded SCA will increase investments in SentinelOne's AI-powered Singularity(TM) Platform within AWS Marketplace, empowering enterprises to quickly and easily access end-to-end protection from a unified, AI-powered platform. "SentinelOne is focused on AI-powered security that protects customers against today's machine-speed attacks and tomorrow's novel threats. AWS has proven to be an increasingly strategic collaborator when it comes to delivering on that promise and accelerating our shared mission," said Gregor Stewart, Vice President, AI and Machine Learning Engineering, SentinelOne. "By taking advantage of AWS AI infrastructure and Amazon Bedrock to train, tune, and serve our own models, we can give AWS customers access to today's best generative AI security analyst - and future Purple AI innovation - delivered entirely inside AWS."

09:18 EDT Renovaro BioSciences presents insights on Oxford Nanopore sequencing - RenovaroCube announced the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress - on October 16, 2024. This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA derived from blood plasma to detect key copy number alterations in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. "The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations which characterize the copy number landscape of lung cancer tissues-traditionally assessed through tissue biopsy," said Khashayar Roohollahi, senior scientist at RenovaroCube. Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.

09:16 EDT C.H. Robinson $900M drop trailer business surpasses half million loads - Global logistics company C.H. Robinson, the fourth-largest drop trailer provider in North America, has already moved half a million drop trailer shipments this year on its way to record-setting volume. In an industry that has historically considered drop trailer the domain of asset carriers, the 3PL is celebrating its 25th year of offering the service. "We pride ourselves on growing with our customers' needs, and our growth in drop trailer is an absolute testament to that," said Michael Castagnetto, President of C.H. Robinson's North American Surface Transportation division. "Drop trailer has always been in our DNA. As early as 1905, our teams were strategically optimizing the drop-off and pick-up of wooden carts for merchants. Today, as a modern 3PL serving nearly every industry, we continue to be a leader in meeting our customers' ever-evolving drop trailer needs." C.H. Robinson Drop Trailer Plus is a $900M service line for the company, representing over 10% of its truckload volume. The service includes dry van, temp control and flatbed modes. Customers get access to C.H. Robinson's trailer pool and the trailers of the largest network of carriers in North America.

09:14 EDT Carlisle to acquire EPS insulation segment of PFB Holdco for $259.5M in cash - Carlisle announced that it has entered into a definitive agreement to acquire the expanded polystyrene, or EPS, insulation segment of PFB Holdco, Inc., a portfolio company of The Riverside Company, composed of the Plasti-Fab and Insulspan brands. Plasti-Fab is a vertically integrated provider of EPS insulation products across Canada and the Midwestern United States. Under the terms of the agreement, Carlisle will purchase Plasti-Fab for $259.5M in cash. The purchase price represents 6.7x on adjusted EBITDA for the twelve months ended August 31, inclusive of run-rate cost synergies. Plasti-Fab is headquartered in Calgary, Alberta, and has eight manufacturing locations across Canada and three in the United States serving the commercial, residential, and infrastructure construction markets. Plasti-Fab generated revenue of $109M for the twelve months ended August 31. The acquisition, which is subject to customary closing conditions, is expected to close in the fourth quarter of 2024.

09:11 EDT Tegna, Dallas Mavericks expand distribution to eight additional stations - Tegna and the Dallas Mavericks announced that eight additional stations will join six owned by Tegna to bring all Mavericks games not exclusively televised nationally to approximately 14M people in Texas, for free over-the-air.

09:10 EDT Energy Recovery announces $12M in contracts for PX Pressure Exchanger - Energy Recovery announced contract awards totaling over $12M for its PX Pressure Exchanger energy recovery devices for three seawater reverse osmosis desalination projects in the United Arab Emirates. The plants include capacity totaling close to 1 million cubic meters per day, and the orders are expected to ship by Q4 2024. These contracts have previously been reported in the company's financial guidance. One of the recently awarded contracts will include PX installations on a floating desalination barge in the Arabian Gulf, which will produce fresh water offshore before pumping it back to the mainland. Offshore desalination facilities eliminate the need for swaths of coastal land, which is often limited and expensive, making it a viable option for densely populated coastal regions. The contracts in the United Arab Emirates will incorporate both the PX Q400 and PX Q300 models, which offer operational sound levels at just 79 decibels. This will also create safer and better workplace environments for these SWRO plants.

09:09 EDT Amylyx announces HELIOS clinical trial meets primary endpoint - Amylyx announced topline data from the Phase 2 open-label HELIOS clinical trial of AMX0035 in 12 adults living with Wolfram syndrome. Wolfram syndrome is a rare, progressive, monogenic disease impacting approximately 3,000 people in the U.S. HELIOS showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with AMX0035, the study's primary efficacy endpoint, in contrast to the expected decrease in pancreatic function with disease progression. Similar overall improvements or stabilization were observed across all secondary endpoints, including hemoglobin A1c, time in target glucose range assessed by continuous glucose monitoring, and visual acuity. Patient- and physician-reported global impressions of change showed disease stability or improvement in all participants, meeting prespecified responder criteria. In addition, longer-term data for all participants who completed Week 36 and Week 48 assessments showed sustained improvement over time. Data from HELIOS are being presented at the International Society for Pediatric and Adolescent Diabetes 50th Annual Congress and during a webcast held by the company. The analysis performed includes Week 24 data for all 12 participants and data for all participants who completed their Week 36 and Week 48 assessments as of the data cutoff. The primary efficacy endpoint of the trial measures change from baseline in C-peptide, an established, objective laboratory measure of pancreatic beta cell function and a surrogate marker of glycemic control, assessed using a mixed meal tolerance test at Week 24. Secondary and exploratory outcomes include the assessment of other diabetic measures and other domains affected by the disease. HELIOS showed improvements in its primary endpoint of C-peptide response with a change from baseline to Week 24 at 120 minutes of +3.8 minutes*ng/mL in the Intent to Treat group and +20.2 min*ng/mL in the Per Protocol group. In addition, as outlined in the table below, participants receiving AMX0035 had improved glycemic control, as measured by markers of glucose metabolism; improved visual acuity in some participants, as measured by the Snellen chart; and improvement or stabilization of the disease, as measured by the Clinician Reported Global Impression of Change and Patient Reported Global Impression of Change. The safety profile of AMX0035 in HELIOS was consistent with prior safety data. AMX0035 was generally well-tolerated. All adverse events were mild or moderate, and there were no serious AEs related to AMX0035 treatment. The most common AE was diarrhea.

09:08 EDT Nephros delivers disaster response to support hopstials, care facilities - Nephros announces its rapid response to the recent hurricanes which devastated parts of the southeastern United States. Leveraging its significant disaster and emergency response capabilities, Nephros provided crucial water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe supply of water to patients and staff amid recovery efforts. Following natural disasters, access to clean, safe water is paramount for healthcare facilities, where contaminated water may severely compromise patient care and operations. The deployment of Nephros' advanced filtration products enables and ensures reliable access to purified water during critical situations.

09:07 EDT Flex to acquire Crown Technical Systems for $325M - Flex has entered into a definitive agreement to acquire Crown Technical Systems, a provider of fully integrated power distribution and protection systems, for $325M in an all-cash transaction. The transaction is expected to be accretive in the first year after closure. Crown Technical Systems has a set of customers spanning utilities, data centers, and power generation, with facilities in California, Texas, and Canada. Crown Technical Systems is expected to generate revenue of approximately $120M and high-teens EBITDA margin in FY25, which ends on March 31, 2025. The transaction is expected to close no later than December 2024, subject to customary closing conditions, including regulatory approval.

09:05 EDT Mullen Automotive regains full Nasdaq compliance - Mullen Automotive received formal notice from The Nasdaq Stock Market confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Mullen is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market. Based on the foregoing, the previously scheduled Nasdaq hearing before the Panel has been cancelled and the matter is now closed. Pursuant to applicable Nasdaq procedures, the Company anticipates being removed from Nasdaq's list of noncompliant companies within approximately four business days from the Oct. 16, 2024, receipt of Nasdaq's notification of compliance.

09:04 EDT Progress Software announces latest release of Progress Flowmon - Progress announced the latest release of Progress Flowmon, the network observability platform with AI-powered detection for cyberthreats, anomalies and fast access to actionable insights for greater network and application performance across hybrid cloud ecosystems. With today's release, the Flowmon platform enhances IP search efficiency up to tenfold with innovative IP address indexing that empowers network administrators to swiftly track network activities tied to specific IP addresses. The result is a significant reduction in the time needed for data analysis and troubleshooting, providing robust protection for optimal network performance.

09:03 EDT Kezar board rejects Concentra proposal, adopts stockholder rights plan - Kezar Life Sciences announced that its board has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the assistance of its independent financial and legal advisors, the board unanimously concluded that the Concentra proposal substantially undervalues the company. The proposal would result in an implied equity value for Kezar stockholders that is materially below Kezar's available liquidity. Accordingly, the board determined that the proposal is not in the best interests of Kezar and its stockholders. In addition, in response to Concentra's proposal and Concentra and its affiliates' rapid accumulation of 9.9% of Kezar's outstanding common stock, the board has adopted a limited duration stockholder rights plan, effective immediately. The rights plan does not prevent the board from engaging with parties or accepting an acquisition proposal, including from Concentra, if the board believes that it is in the best interests of Kezar and all of its stockholders. The rights plan is similar to other plans adopted by publicly held companies in comparable circumstances, and does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future board to redeem the rights. In connection with the adoption of the rights plan, the board declared a dividend of one preferred share purchase right for each outstanding share of Kezar's common stock as of the close of business on October 28, the record date. The rights will be exercisable only if a person or group acquires or launches a tender or exchange offer to acquire beneficial ownership of 10% or more of Kezar's outstanding common stock. Any stockholders with beneficial ownership of Kezar's outstanding common stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the rights plan. Once the rights become exercisable, each Right will entitle its holder to purchase, for $7.16, additional shares of Kezar's common stock having a market value of twice such exercise price. In addition, the rights plan has customary flip-over and exchange features. The rights plan will expire on October 17, 2025, unless the rights are earlier redeemed or exchanged by Kezar.

09:02 EDT Lottery.com outlines future growth plans following registration statement - Lottery.com announced that the U.S. Securities and Exchange Commission has declared the Company's Form S-1 Registration Statement effective on October 16, 2024. The Company's turnaround efforts which began in late 2022, were designed to address numerous operational and financial challenges, which included regulatory inquiries; regaining full compliance with Nasdaq listing and SEC reporting requirements; staff restructuring; as well as overall capital shortages. With the successful registration of the Company's registration statement, Lottery.com is now poised to enter a new phase of strategic growth and market expansion. The Registration Statement, while effective, allows the covered selling securityholders to publicly resell the securities covered by the Registration Statement, subject to the satisfaction by selling securityholders of certain SEC requirements in connection with any such resale. The Registration Statement also provides for an offering by the Company of up to 50 million shares of Common Stock at $3.00 per share. Key milestones and strategic initiatives include: Lottery.com Expansion: The Company is now poised to work to operationalize its US operations across multiple states anticipated by the end of 2025. International expansion is also planned, with the intent to introduce a new gaming model in 2025 aimed at revolutionizing the global lottery market. Sports.com Growth: Earlier this year, the Company launched the new Sports.com platform in partnership with S&MI Ltd, the innovative technology company behind the Sportlocker brand, which has been rebranded as the Sports.com site and app. The Company completed its acquisition of S&MI on September 1, 2024. The platform is designed to deliver immersive live sports content enhanced by cutting-edge 3D technology, with rollouts planned in the U.S., Europe, and the Middle East by mid-2025. The Registration Statement is one key component of the Company's partnership strategy, which, when financing through sales of stock, will help to springboard Sports.com's position to becoming a major player in global sports media and entertainment. Lottery.com is focused on developing proprietary technology and pursuing a "buy and build" growth strategy with its common stock as the primary consideration for acquisitions. With a clear roadmap, Lottery.com is working to enter this next phase with confidence, backed by a highly experienced leadership team and committed funding and business partners.

08:58 EDT Kezar Life Sciences reports PORTOLA trial may proceed, termination of PALIZADE - Kezar Life Sciences announced key clinical development updates. The IDMC overseeing the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH recommended that the trial may proceed without modification following its third scheduled meeting. The IDMC examined safety data from all patients enrolled in the trial, including data from patients who completed the blinded treatment period and continued to the open-label extension portion of the trial which includes an additional 24 weeks of treatment. Three members of the IDMC, including the committee chair, are also members of the IDMC overseeing the PALIZADE study of zetomipzomib in LN. To date, no Grade 4 or 5 serious adverse events, or SAEs, have been observed in the PORTOLA trial which is being conducted at clinical sites in the United States. Kezar has completed enrollment of PORTOLA and plans to report topline data in the first half of 2025. Kezar has also made the strategic decision to terminate the PALIZADE Phase 2b clinical trial in patients with active LN and focus clinical development efforts of zetomipzomib in AIH, a rare disease with a significant unmet medical need. PALIZADE was recently placed on clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 SAEs that occurred in patients enrolled in the Philippines and Argentina. Kezar will unblind the trial and perform a full investigation into all safety events from the study. As of termination, 84 patients were enrolled, and Kezar will report available data from PALIZADE at a later date. Kezar's unaudited cash position is approximately $148M, including cash, cash equivalents and marketable securities, as of September 30. This cash estimate is a preliminary estimate and based on information currently available to management, and this estimate could change.

08:52 EDT HeartBeam says Robert Eno appointed Chief Executive Officer, effective Oct 21 - HeartBeam announced that Robert Eno has been appointed Chief Executive Officer CEO , effective Monday, October 21 . The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work towards securing the foundational FDA 510 k clearance for its vector-based technology and prepares for commercialization and growth. As part of the long-planned transition, Branislav Vajdic, Ph.D., Founder and current CEO, will move into the role of President. In this role, Dr. Vajdic will focus on further innovating on the Company's groundbreaking vector-based technology, driving research and development efforts, and advancing artificial intelligence AI applications.

08:51 EDT Lucid Group sinks 19% to $2.67 after 262M share sale

08:49 EDT Mawson Infrastructure reports September revenue $4.15M, up 65% year-over-year - Rahul Mewawalla, CEO and President said, "We are excited to achieve another month of strong results, including a 65% year-on-year increase in overall monthly business revenue. In addition, we have built and grown a significant enterprise-grade digital colocation business that now represents a multi-million-dollar business across multiple customers. We also are excited about advancing our recent expansion into AI and HPC markets with our innovative and solutions-driven approach to growing our overall business. We are also extremely proud of our carbon-free and sustainable energy approach, including nuclear, which we believe will be increasingly critical to sustainable growth in global compute capacity, particularly in the AI and HPC markets going forward." Unaudited financial and operational highlights for September 2024: Total Monthly Revenue up 65% Y/Y from September 2023 to about $4.15 million. Digital Colocation Monthly Business Revenue was $3.36 million, up from zero in Sep 2023 with diversified enterprise-grade customers. Energy Management Monthly Business Revenue up 271% Y/Y to $0.62 million and Self-mining Bitcoin Monthly Business Revenue of $0.18 million. Signed lease extension at Midland, PA. facility to September 2027 with overall lease tenure through September 2036. Completed Phase 1 of construction including groundworks at Perry County, OH facility, which is expected to increase Mawson's Total Capacity to 153 MW upon completion.

08:46 EDT Sonnet BioTherapeutics regains compliance with Nasdaq - Sonnet BioTherapeutics received notice on October 16, 2024 from The Nasdaq Stock Market that the Company regained compliance with the bid price requirement in Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, in application of Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from October 16, 2024. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff finds the Company again out of compliance with the Bid Price Rule that was the subject of the exception, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be at that time delisted from Nasdaq.

08:41 EDT Gaucho Group's Algodon Fine Wines introduces winemaker's selection to the U.S. - Algodon Fine Wines announces the release of its newest and most anticipated addition to its wine catalog: The Mauro Nosenzo Black Label Signature Blend 2021. For the first time ever, this exceptional winemaker's selection is available in the United States, allowing American wine lovers to experience the passion and craftsmanship behind this limited-edition wine. Produced with dedication and expertise by Algodon's head winemaker, Mauro Nosenzo, this handcrafted winemaker's selection is the epitome of his profound connection to Argentina's renowned San Rafael terroir. This unique wine, produced in an exclusive release of just 2,000 bottles, features a carefully curated blend of six of Argentina's most distinguished varietals: Malbec, Bonarda, Cabernet Sauvignon, Merlot, Syrah, and Cabernet Franc.

08:40 EDT IGC Pharma announces patient enrollment in Phase 2 trial of IGC-AD1 - IGC Pharma announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication. IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties and acts as an inflammasome inhibitor, addressing key pathways involved in the neuroinflammation, oxidative stress, and neurotransmitter imbalances that are implicated with agitation in Alzheimer's disease pathology. IGC Pharma have 12 U.S. trial sites under contract and is on target to enroll additional sites in Canada to increase population diversity. The trial will enroll 164 patients with one half, the treated group, receiving IGC-AD1, and the other half, the control group, receiving a placebo.

08:39 EDT LM Funding reports bitcoin holdings valued at $9.6M as of Sept. 30 - The Company estimates that the value of its 142.3 Bitcoin holdings on September 30, 2024, was approximately $9.6 million, based on an estimated October 16, 2024 BTC price of $67,500.

08:37 EDT Energous appoints Mallorie Burak as permanent CEO - Energous announced the appointment of Mallorie Burak as its permanent CEO and as a member of the board, each effective immediately. Burak will continue to serve as the company's CFO. Building on her recent roles as interim CEO and CFO, Burak brings executive leadership, a range of experiences, and a broad skillset to Energous. Burak joined Energous Wireless Power Solutions in January as CFO.

08:37 EDT Banzai announces significant enhancements to its Demio platform - Banzai International (BNZI) announced significant enhancements to its Demio platform through deeper integration with Salesforce (CRM), the industry leading AI CRM company. These new features address key operational challenges faced by marketing teams, delivering an improved level of precision in webinar data management, from automated lead capture to real-time UTM tracking. Joe Davy, CEO of Banzai, emphasized the power of this upgraded integration: "By deepening our connectivity with Pardot, we're offering marketers a more scalable, data-rich experience. This isn't just a product enhancement; it's a strategy shift that will drive better outcomes with less effort."

08:35 EDT ExlService was selected by Convex Group for multiyear agreement - EXL was selected by Convex Group Limited, the international specialty insurer and reinsurer, for a multiyear engagement focused on accelerating delivery of its business operations. The program will improve efficiency and customer experience, delivering a more cost-effective, scalable and resilient operating model. As part of Convex's strategically differentiated approach to outsourcing, EXL will help deliver the next phase of development in operational excellence and efficiency, enhancing workflows and delivering integrated data-enriched management information, analytics and AI across the breadth of the operating model.

08:33 EDT Richtech Robotics expands agreement with Ghost Kitchens - Richtech Robotics announces that it is expanding its restaurant operations model with the signing of a binding Letter of Intent, LOI, with Ghost Kitchens America. Under the terms of the LOI, Richtech Robotics agreed to enter into a franchise agreement with Ghost Kitchens America, pursuant to which the Company will acquire exclusive rights to operate 20 Walmart-located restaurants in Arizona, Colorado, and Texas. These restaurants will be directly managed by Richtech Robotics' subsidiary, AlphaMax Management, with the aim of optimizing restaurant operations through robotics and AI cloud technology. Each location is expected to generate between $700 thousand and $2 million in annual revenue.

08:33 EDT Bridgeline Digital updates HawkSearch's Rapid UI Framework - Bridgeline Digital announced a major update to HawkSearch's Rapid UI Framework, a powerful component-based framework that accelerates the integration of Smart Response into their search interfaces. The new version includes a new component for HawkSearch's Smart Response, a new GenAI capability to complement Smart Search's features as announced earlier in the year. Smart Response, now powered by Generative AI, delivers a transformative experience for eCommerce users. It goes beyond traditional search results by enabling interactive conversations, summarizing extensive product information, and comparing items directly within the search interface. With the ability to customize "Agents" to align with brand tone, merchandisers can now fine-tune responses to suit specific customer needs. The updated version has comprehensive documentation and implementation examples available via the HawkSearch Developer Portal.

08:22 EDT Zentek provides market update on ZenGUARD antimicrobial surgical masks - Zentek (ZTEK) provided an update on recent commercialization activities for its ZenGUARD Antimicrobial Surgical Masks. As previously announced on July 24, 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein (HSIC) that saw ZenGUARD Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program and the unique value proposition ZenGUARD Antimicrobial Surgical Masks bring to dental practitioners and their patients, the Company is now seeing increased demand from Henry Schein. Zentek continues to explore opportunities in other markets including in the beauty space and in international healthcare and dental markets where demand for surgical masks is expected to be more stable long term.

08:20 EDT Stepstone Group adds Marketing, RIA relationship executives - StepStone Private Wealth announced that it has hired two senior-level executives in Marketing and RIA relationship management to support its continued growth. Berta Aldrich has been named Managing Director and Global Head of Private Wealth Marketing and David Robbins has been named Director of Enterprise RIA Relationship Management. Both joined SPW earlier this month.

08:17 EDT Windtree Therapeutics announces issuance of istaroxime patent for Japan - Windtree Therapeutics announced the issuance of an istaroxime patent for Japan. The patent is entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure." The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.

08:15 EDT Total Energy files notice to undertake normal course issuer bid - Total Energy Services has filed a Notice with the Toronto Stock Exchange to undertake a normal course issuer bid that will begin on October 21, 2024 and expire on October 20, 2025. Total Energy has been informed that the TSX has accepted its notice to make the normal course issuer bid. All purchases of common shares will be effected through the facilities of the TSX and one or more of the Canadian alternative trading systems and all Shares purchased will be cancelled by the Company. As of today, there are 38,194,658 Shares issued and outstanding. In connection with the normal course issuer bid commencing on October 21, 2024, Total Energy may purchase up to 1,909,732 Shares, being 5% of the total number of outstanding Shares on October 16, 2024, during the period from October 21, 2024 to October 20, 2025, subject to a maximum daily purchase limit of 7,620 Shares based on an average daily trading volume for the last six calendar months of 30,482 Shares. On October 17, 2023, Total Energy announced its intention to undertake a normal course issuer bid, which remained in effect during the 12-month period ending on October 18, 2024. Under that normal course issuer bid Total Energy purchased a total of 1,998,750 Shares at an average price of $9.58 per Share, which was the maximum number of Shares permitted to be purchased by Total Energy under such normal course issuer bid.

08:14 EDT Worksport implements cost-saving measures to result in 2025 savings of $1.5M - Worksport announced the implementation of strategic cost-saving measures designed to enhance operational efficiency and drive long-term growth. The Company forecasts these actions will result in $1.5 million in expense savings in 2025, along with an additional $0.5 to $1 million in related savings, without negatively impacting revenues or growth. Key Highlights: Strategic Cost Savings: Initiatives begin immediately and target a reduction of recurring expenses. These initiatives are expected to improve margins and enhance cash preservation. Growth Focus: The Company aims for significant revenue growth in 2025, targeting cash flow positivity by expanding its tonneau cover business line and launching clean tech products. The newly enacted cost saving initiatives are expected to expedite the Company's progression to this goal. Product Launches on Schedule: No material delays are expected for three new products, including the highly anticipated AL4 Premium Tonneau Cover, the COR Portable Energy System, and the SOLIS Solar Cover. Upcoming Catalysts: Immediate benefits are expected in Q4 2024, with further positive financial impact anticipated in Q1 2025. Worksport is aggressively pursuing growth in its tonneau cover business line, projecting: Cash Flow Positivity in 2025: Capitalizing on high-demand products and expanding market share. Significant Revenue Growth: Targeting a multiple increase over year-end 2024 revenues. Product Launches and Upcoming Catalysts: AL4 Premium Tonneau Cover: Expected Release: Late Q4 2024. Features: Innovative four-fold design offering enhanced functionality and margins. Market Potential: Four-fold covers are seen as the most in-demand models in the market, and this cover is expected to propel Worksport toward nine-figure revenue in the short to midterm. Worksport COR Portable Energy System, and 3. SOLIS Solar Cover: Current Phase: Recently entered alpha release. Next Steps: Ongoing real-world testing, design optimization, and media engagement leading to a pre-order campaign and larger beta release. Manufacturing Partnerships: The Company is proud to announce it is in advanced discussions with a globally recognized manufacturer to produce these units. Continued Commitment to Innovation. Worksport remains highly engaged in research and development, with a focus on: Terravis Energy's Extreme Climate Heat Pump: The Company is looking forward to sharing exciting advancements of this subsidiary soon. Ongoing R&D Efforts: The Company recently provided an update on 19 new models it has added to its product catalogue in just the last 6 months, and it looks forward to sharing additional updates as they occur.

08:12 EDT Uniti Group announes new 20-year contract award from customer in Alabama - Uniti Group announces a new 20-year contract award from a strategic hyperscale customer in Montgomery, Alabama, one of Uniti's existing 30+ enterprise markets. Anchored by this hyperscaler contract award, Uniti will construct 90 route miles of new multi-conduit systems and high-strand count fiber cables. This new route will connect key data center locations and points-of-presence in a ring configuration within the Montgomery metropolitan area. Expected delivery of the fiber rings will take place throughout late 2025 and into early 2026.

08:10 EDT Acrivon Therapeutics to presents data on deployment of AP3 platform - Acrivon Therapeutics announced the company will be presenting data on the ability of its AP3 platform to uniquely enable the clinical development of ACR-368 and the discovery and design of ACR-2316 at two upcoming scientific congresses: Human Proteome Organization World Congress taking place from October 20-24, 2024 in Dresden, Germany and EORTC-NCI-AACR Symposium taking place from October 23-25, 2024 in Barcelona, Spain. "We are excited to have these three presentations highlighting the unique and actionable capabilities of AP3 featured at two premier scientific conferences in Europe this month," said Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon and president and CEO of the company's research subsidiary Acrivon AB in Lund, Sweden. "The presentations are the product of the efficient integration of our two teams of research scientists. In Lund, we utilize and leverage a world-class mass spectrometry and precision phosphoproteomics infrastructure. In Boston, we generate data and actionable insights through AP3 using state-of-the-art, fully scripted, algorithm-based, machine learning-enabled pathway and biomarker analyses. Our AP3 platform thus enables us to overcome many of the challenges facing the biopharma industry, including the discovery of clinical biomarkers, the identification of resistance mechanisms, indication finding, and prediction of patient responders. We have applied actionable insights from AP3 to the streamlined clinical development of ACR-368, and to rapidly design, discover and advance ACR-2316 into monotherapy clinical development in selected tumor types predicted sensitive with our AP3 platform. We firmly remain a science- and data-driven company, and it is always gratifying to be able to share our work at prestigious scientific conferences."

08:09 EDT Pliant Therapeutics highlights INTEGRIS-PSC Phase 2a data on bexotegrast - Pliant Therapeutics announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases, in San Diego, California November 15 - 19. Bexotegrast is an oral, small molecule, dual selective inhibitor of alphavss6 and alphavss1 integrins that is being studied for the treatment of idiopathic pulmonary fibrosis and PSC. The oral presentation titled "Bexotegrast, an oral inhibitor of alphavbeta6 and alphavbeta1 integrins, was shown to improve markers and symptoms of cholestasis and stabilized markers of liver fibrosis in participants with primary sclerosing cholangitis: Week 24 results from the Phase 2 INTEGRIS-PSC trial," will be delivered by Kris Kowdley M.D., AGAF, FAASLD, FACP, FACG, Director, Liver Institute Northwest and Professor of Medicine, Elson S. Floyd College of Medicine at Washington State University.

08:08 EDT Hydrofarm announces Toler to retire as CEO, Lindeman to succeed - Hydrofarm Holdings announced plans for a transition of its leadership team. As part of this plan, Bill Toler, the Company's Chairman and Chief Executive Officer, CEO, has announced that he will be retiring from his position as CEO and will become Executive Chairman of the Board of Hydrofarm, effective as of January 1, 2025. John Lindeman, currently Executive Vice President and Chief Financial Officer, CFO, will become CEO. Also as part of the executive leadership plan and occurring concurrently with Mr. Lindeman's transition to CEO: Mark Parker, currently Executive Vice President, EVP, of Sales and Business Development, will be promoted to the role of President; Kevin O'Brien, currently Chief Accounting Officer, CAO, will be promoted to CFO; and Erica Ackerman, currently Corporate Controller, will assume the additional role of CAO.

08:06 EDT NaaS partners with leading charging station operator in Fujian Province - NaaS Technology announced a strategic partnership with a leading regional charging station operator in Fujian Province. This collaboration will integrate over 100 charging stations and 1,600+ DC fast chargers into NaaS's strategic partner Kuaidian's charging service network, broadening NaaS's presence in major cities such as Xiamen and Fuzhou and extending the Company's regional coverage to smaller cities including Ningde, Longyan, Sanming, and Putian. The partnership will focus on charging facility interconnectivity, targeted traffic guidance, and seamless payments, enhancing the availability and convenience of charging services in the region. As of August 2024, Fujian had over 700,000 NEVs and more than 105,000 public charging piles, with Xiamen and Fuzhou experiencing robust growth in NEV penetration. Xiamen's NEV ownership currently exceeds 190,000, representing 10% of total vehicle ownership, surpassing the national average of 7.4%. Meanwhile, monthly NEV sales penetration rates in Xiamen and Fuzhou are approaching 55%, also outpacing the national average.

08:05 EDT Poseida Therapeutics nominates new CAR-T candidate under Roche collaboration - Poseida Therapeutics (PSTX) announced the nomination of a new development candidate under its collaboration with Roche (RHHBY). The nomination triggered a $15M milestone payment from Roche to Poseida. The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma. The large capacity of Poseida's non-viral transposon-based DNA delivery system enables the insertion of genes for two full length chimeric antigen receptors into T stem cell memory cells. Poseida and Roche now have three programs under their collaboration, which was established in August 2022 to develop allogeneic CAR-T therapies directed to hematologic malignancies.

08:05 EDT Life Time Group expands relationship with National Academy of Sports Medicine - Life Time announced the renewal of its long-standing alliance with the National Academy of Sports Medicine, continuing its commitment to professional development opportunities for its dynamic personal trainers, stretch specialists and group fitness instructors. Through the collaboration, Life Time trainers and instructors have complimentary access to the NASM ClubConnect platform, which includes continued education courses, reduced rates for certifications and credentials and exclusive access to workshops. Along with the company's own certification process, this access ensures Life Time trainers and instructors remain at the forefront of the wellness industry, giving them ample skills to help members live healthier, happier lives.

08:04 EDT Wyndham Hotels signs exclusive development agreement with NILE Hospitality - Wyndham Hotels & Resorts has signed an exclusive development agreement with NILE Hospitality LLP to introduce its Microtel by Wyndham brand to India, marking the eighth Wyndham brand to debut in the country. This strategic alliance enables Wyndham to leverage a leading regional third-party developer and operator to bring its award-winning brand to India. With Wyndham's global presence and NILE's expertise across India, the company anticipates opening 40 Microtel hotels by 2031, all of which will be direct franchisees of Wyndham, as part of its ambitious and robust growth strategy. The agreement underscores the company's commitment to expanding in one of the world's most dynamic growing hospitality markets, where it currently has 60 hotels open throughout India and expects to grow by at least 25% in the next 18 months.

08:03 EDT Rani Therapeutics announces new preclinical PK data on GLP-1 - Rani Therapeutics announced new pharmacokinetic, PK, data from a preclinical study evaluating a GLP-1, GIP and glucagon receptors incretin triagonist with a delivery method mimicking the RaniPill route of administration. A previous study with this incretin triagonist delivered transenterically demonstrated pharmacodynamic effects comparable to subcutaneous injection. Rani also previously completed a study demonstrating oral delivery of GLP-1 receptor agonist with high bioavailability via the RaniPill capsule. A single dose of drug delivered via either transenteric or SC routes elicited rapid decreases in body weight and serum lipids. Weight loss observed following transenteric delivery was 9.7 +/- 2.5 % versus 6.9 +/- 2.1 % following SC injection and is believed to be due to early satiety leading to reduced caloric intake. The drug was well tolerated in both groups with no serious adverse events, SAEs, observed or changes in safety markers examined.

08:03 EDT AbbVie's Vyalev approved by FDA in advanced Parkinson's disease - AbbVie announced that the FDA has approved Vyalev as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The approval was supported by the Phase 3 study evaluating the efficacy of continuous subcutaneous infusion of Vyalev in adult patients with advanced PD compared to oral immediate-release carbidopa/levodopa, along with a 52-week, open-label study which evaluated the long-term safety and efficacy of Vyalev. Findings showed patients receiving Vyalev demonstrated superior improvement in motor fluctuations, with increased "on" time without troublesome dyskinesia and decreased "off" time, compared with oral CD/LD IR.1 "On" time refers to the periods of time when patients are experiencing optimal motor symptom control while "off" time is when symptoms return. The majority of adverse reactions with Vyalev were non-serious and mild or moderate in severity. Coverage for Medicare patients is expected in the second half of 2025.

08:02 EDT Eterna, Factor announce license, collaboration agreement - Eterna Therapeutics and Factor Bioscience announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell-based cell therapy products (in particular iPSC derived mesenchymal stem cells that are engineered to express certain cytokines utilizing Factor's cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.

07:54 EDT ZyVersa Therapeutics CEO highlights obesity development plans for IC 100 - ZyVersa Therapeutics announces that Stephen Glover, CEO has issued a Letter to Shareholders highlighting obesity development plans for Inflammasome ASC Inhibitor IC 100, which read in part, "As announced in late July, ZyVersa selected obesity with metabolic complications as the lead indication for Inflammasome ASC Inhibitor IC 100. Selection of this indication is consistent with our mission to restore health and transform patient lives through innovation. Although GLP-1 agonist therapy has changed the treatment paradigm for obesity with unsurpassed weight loss, significant unmet medical needs remain. A critical unmet need is for therapies to address the chronic systemic inflammation of obesity that causes life-altering metabolic comorbidities such as cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease, and even neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Based on IC 100's highly differentiated mechanism of action, it is anticipated that IC 100 will control the chronic systemic inflammation of obesity, attenuate development and/or progression of associated metabolic comorbidities, and augment weight loss when added to GLP-1 agonist therapy. Selection of obesity with metabolic complications as the lead indication for IC 100 is also consistent with ZyVersa's goal to drive shareholder value. The obesity drug revolution has led to a 10-fold increase in private venture dollars flowing into the category over the last 5 years and high deal volume. This is expected to continue with investment opportunities in R&D innovation to develop GLP-1 agonist add-on therapies to address unmet needs. This is exemplified by some of the latest transactions: Oct 10, 2024: Lilly announced up to $1.4 billion plus upfront payment and royalties for expanded collaboration with KeyBioscience for rights to dual amylin calcitonin receptor agonists for obesity and complications. September 25, 2024: Bioage announced an upsized $198 Million IPO driven by their APJ agonist in development for muscle preservation and improved metabolism to be used in combination with GLP-1 agonist therapy. September 23, 2024: Sanofi announced a $27 Million strategic investment in Ventyx Biosciences' NLRP3 inhibitor VTX3232, which is phase 2 for obesity with cardiovascular complications and Parkinson's disease. September 4, 2024: Lilly announced a collaboration with Haya Therapeutics for up to $1 Billion for drug discovery in obesity and related metabolic conditions. August 10, 2024: Novo Nordisk announced acquisition of Inversago Pharma, valued up to $1.075 Billion. Inversago develops CB1 receptor-based therapies for obesity, diabetes, and complications associated with metabolic disorders. We are excited about the potential for Inflammasome ASC Inhibitor IC 100 as an add-on therapy to GLP-1 agonists to help restore health and transform the lives of patients living with obesity and its associated comorbidities. We recently reviewed the preclinical data supporting IC 100 with our newly formed Obesity, Metabolic, and Inflammatory Disease Scientific Advisory Board. Advisory Board members indicated that IC 100's mechanism of action supports its rationale for use as an add-on treatment to GLP-1 agonists to address the chronic inflammation of obesity and its associated metabolic complications. They also provided excellent input on our planned DIO obesity model studies to strengthen their design and endpoints for proof-of-concept of IC 100's potential as a treatment for obesity with metabolic complications. Following are key IC 100 short-term obesity development milestones that we expect to achieve: Q4-2024: Initiate IC 100 monotherapy study using semaglutide as a comparator in DIO mice. Q1- 2025: Initiate IC 100 combination study with semaglutide in DIO mice. Q2-2025: File IND. Q3-2025: Initiate IC 100 phase 1 trial in healthy overweight subjects with a BMI 27 - 30. We appreciate your current and ongoing support that enables us to progress IC 100's development program to drive shareholder value."

07:51 EDT Elevance Health authorizes $8B increase to common stock repurchase program - "As of September 30, 2024, the company had approximately $3.1 billion of Board approved share repurchase authorization remaining. On October 15, 2024, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized an $8.0 billion increase to the common stock repurchase program. The company intends to utilize this authorization over a multi-year period, subject to market and industry conditions."

07:42 EDT Theratechnologies unveils study design of PROMISE-US trial of ibalizumab - Theratechnologies disclosed the study design and baseline characteristics of participants in the Prospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States, PROMISE-US. The study seeks to fill a critical gap in long-term clinical outcomes for heavily treatment-experienced, HTE, people with HIV, PWH, while illuminating factors contributing to maintenance of virologic control. The study's primary objective is to evaluate the long-term efficacy and durability of ibalizumab in combination with other antiretroviral therapies by comparing the clinical outcomes of patients receiving ibalizumab versus matched patients not receiving ibalizumab.

07:39 EDT Palvella Therapeutics apponts Matthew Korenberg as CFO - Palvella Therapeutics announced the appointment of Matthew Korenberg as CFO, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Korenberg joins Palvella from Ligand Pharmaceuticals Inc. (LGND), where he served as President and COO since 2022 and CFO from 2015 to 2022. In July 2024, Palvella and Pieris Pharmaceuticals, Inc. (PIRS) announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

07:34 EDT Anavex announces preliminary biomarker results from Phase 2 study of ANAVEX 3-71 - Anavex Life Sciences announced preliminary electroencephalography biomarker results from the Part A of the ongoing placebo-controlled Phase 2 clinical study of ANAVEX 3-71 for the treatment of schizophrenia. Part A of the Phase 2 study ANAVEX 3-71-SZ-001, was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX 3-71 90 mg daily, or oral ANAVEX 3-71 180 mg daily for 10 days. Preliminary results demonstrated a dose-dependent effect of ANAVEX 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX 3-71 compared to placebo resulted in improvements in 40 Hz Auditory Steady-State Response Inter Trial Coherence and Resting State Alpha Power, both of which were increased. These effects were most pronounced in the higher dose group demonstrating a dose-dependent pharmacodynamic effect. These results provide evidence of CNS target engagement and potential therapeutic effects of ANAVEX 3-71 in schizophrenia. The observed changes reversed known EEG and ERP biomarker abnormalities associated with schizophrenia. These EEG biomarkers correlate with positive, negative, and cognitive symptoms of schizophrenia. Individuals with schizophrenia typically have reduced neural synchrony as measured by 40 Hz ASSR ITC. Improvements in 40 Hz ASSR ITC indicate enhanced neural synchronization, potentially leading to reduced auditory hallucinations, improved executive function, and working memory. Individuals with schizophrenia also typically have decreased resting state alpha power correlating with sensory and behavioral problems. Increases in Resting State Alpha Power reflect improvements in thalamocortical circuits and sensory gating, potentially resulting in reduced irritability and anxiety. ANAVEX 3-71 was well tolerated, with no serious adverse events reported. Oral ANAVEX 3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains of schizophrenia without the side effects of standard of care antipsychotics. ANAVEX 3-71 has previously demonstrated long-lasting, pro-cognitive effects and behavioral improvements in animal models of neurodegenerative diseases, an ability to prevent cognitive decline in animal models, and has shown robust safety signals in healthy volunteers at single doses ranging from 5 to 200 mg once daily. Recent research into the genetic underpinnings of schizophrenia has revealed links between this psychiatric disorder and neurodegenerative disease, suggesting the disorders may share certain mechanisms. Oral ANAVEX 3-71, in addition to the M1 muscarinic receptor activity, the combined SIGMAR1 receptor activity might offer a novel mechanism of action that may address multiple symptom domains without the motor side effects associated with traditional antipsychotics. The currently ongoing Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer treatment duration, will provide more comprehensive data on the efficacy and safety of ANAVEX 3-71 in schizophrenia. Anavex expects data from Part B of the placebo-controlled Phase 2 study in the first half of 2025.

07:32 EDT Algorhythm annon es SeCab entered a MSA with Apollo Tyres - Algorhythm Holdings announced that SemiCab, Inc.'s subsidiary, SMCB Private Solutions, has entered into a master service agreement, MSA, with Apollo Tyres, India's largest tire manufacturer. As a top 10 global tire producer, Apollo generated over $3 billion in sales in 2023, operating in more than 100 countries across Asia, Europe, and North America.

07:20 EDT Appili Therapeutics presents update on ATI-1701 biodefense vaccine candidate - Appili Therapeutics announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili's scientific team, will participate at IDWeek 2024, and present an update on the Appili biodefense program ATI-1701. The conference is being held from October 16-19 2024, at the Los Angeles Convention Center. The poster presentation will provide an update on ATI-1701, Appili's potential first-in-class vaccine candidate for the prevention of tularemia caused by F. tularensis and will summarize the latest findings from preclinical studies. These studies have demonstrated that a single dose of ATI-1701 provides full protection in animal models against lethal tularemia one year after vaccination. Appili secured a $14M funding commitment for ATI-1701 from the United States Air Force Academy, who is working in partnership with the Defense Threat Reduction Agency. These funds along with other potential funding sources, are anticipated to advance the ATI-1701 program to IND submission to the United States Food and Drug Administration in 2025.

07:18 EDT Draganfly showcases drone innovations at Wings of Saskatchewan - Draganfly announces its participation in the upcoming Wings of Saskatchewan event in Regina, from October 30 to October 31, 2024. Draganfly will showcase its latest drone technology advancements, contributing to discussions on industry trends, safety, and regulatory considerations alongside key stakeholders in the aviation sector. The Wings of Saskatchewan Conference, hosted by the Saskatchewan Aerial Applicators Association and the Saskatchewan Aviation Council, serves as a vital gathering for the aviation community. This year's event will bring together leaders from both civil and commercial aviation sectors to discuss technological advancements, regulatory updates, and future trends within the industry. Draganfly will emphasize the need for synergy across the aviation industry at the conference by addressing essential topics, including airspace safety and the regulatory challenges impacting the drone sector. This presentation will spotlight the benefits of enhanced communication and collaboration between fixed-wing, helicopter, and RPAS to promote safe, efficient, and integrated airspace management.

07:17 EDT Irving Resources reports formation of Yamagano, Noto joint venture - Irving Resources has entered into an agreement with Newmont Overseas Exploration, a wholly-owned subsidiary of Newmont Corporation (NEM), and Sumitomo Corporation (SSUMY) in respect of the formation of a joint venture over the Yamagano and Noto properties. The initial interests of the parties in the joint venture are Newmont as to 60%, Irving as to 27.5% and Sumitomo as to 12.5%. Irving will be the initial manager of the joint venture. Newmont has the right to assume the responsibilities of manager at any time.

07:14 EDT SES AI promotes Kang Xu to CTO, signs pact with global electrolyte producer - SES AI announced two major milestones in its AI Initiative: the promotion of Kang Xu, current chief scientist, to chief technology officer, or CTO, to lead the company's AI efforts, effective October 17 and the signing of its first commercial agreement with a global electrolyte producer. This new partnership will harness AI to accelerate Li-Metal and Li-ion electrolyte development across four key applications: EV, heavy-duty trucking, consumer electronics, and grid storage. Kang Xu, an expert in battery electrolyte development with nearly 30 years of experience, joined SES AI as chief scientist in August 2023.

07:12 EDT Nutriband receives Costa Rica MoH approval for Mosquito Repellent Patch - Nutriband has received approval from the Costa Rica Ministry of Health for the production and marketing of its Mosquito Repellent Patch, designed to reduce the risk of mosquito bites and associated health risks associated with exposure to mosquito bites. The Company intends to further expand distribution throughout South and Central America. The Nutriband Insect Repellent Patch contains simple natural ingredients which are used to mask human odors that are attractive to insects. Recommended wear sites include exposed areas of skin such as the neck, arms and legs. The active ingredient in the Nutriband Mosquito Repellent Patch is similar to what is used in mosquito patches that were approved in Africa based on extensive safety and efficacy testing with a goal to reduce the spread of malaria and HIV. Specific country approvals in Africa included Ghana, Nigeria and the Ivory Coast. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Pocono Pharmaceutical will act as exclusive manufacturer for the product.

07:10 EDT Sage Therapeutics to reduce workforce by 33%, prioritize Zurzuvae - Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington's Disease expected later this year. The reorganization is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential. The reorganization is planned to be substantially completed by the end of the fourth quarter of 2024 and expected to: impact over 165 employees, including changes to the leadership team; implement early-stage pipeline prioritization. Anne Marie Cook, senior VP, general counsel; Kimi Iguchi, CFO; Matt Lasmanis, chief technology and innovation officer; Heinrich Schlieker, senior VP of technical operations and Amy Schacterle, senior VP of R&D strategy and business management will depart Sage. Chris Benecchi will take on an expanded role as COO and will oversee finance, information technology, and technical operations in addition to continuing to oversee business development, medical affairs and commercial. Greg Shiferman will be promoted to senior VP, general counsel. Sage expects a non-recurring charge of approximately $26M to $28M associated with the reorganization, primarily incurred in the fourth quarter of 2024. The company anticipates that the implementation of the restructuring will extend its cash runway and expects to provide updated cash runway guidance in the near future.

07:08 EDT Tilray celebrates six years of cannabis legalization in Canada - Tilray Brands celebrates six years of cannabis legalization in Canada, marking its continued leadership as the #1 cannabis producer in the country. Blair MacNeil, President of Tilray Canada, said, "Our success over the past six years is a testament to our unwavering commitment to our consumers and delivering exceptional products that cater to their needs. As the cannabis market continues to evolve, Tilray remains at the forefront of innovation, driving growth and setting the standards for excellence in the global industry."

07:08 EDT Accuray's CyberKnife System shows disease control, safety in NEJM study - Accuray announced that results of the PACE-B - Prostate Advances in Comparative Evidence - trial were published in the New England Journal of Medicine. The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy - SBRT - provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy, while reducing the overall treatment timeframe from up to 39 days of treatment to just five days. The Accuray CyberKnife System was used in the SBRT treated arm of the PACE-B study and showed excellent disease control with low rates of toxicity for men with prostate cancer. Both groups attained high rates of cancer control at five years, with similar rates of 94.6% for CRT and 95.8% for SBRT achieved without the use of androgen deprivation therapy. SBRT was well-tolerated and treatment-related impairment and bother were comparable to CRT. 41% of men treated with SBRT in the study received treatment using the CyberKnife platform.

07:07 EDT Marinus Pharmaceuticals presents clinical data from pivotal phase 3 RAISE trial - Marinus Pharmaceuticals presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous ganaxolone for the treatment of refractory status epilepticus RSE at the Neurocritical Care Society NCS Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June 2024. In the RAISE trial patients with RSE that failed at least two antiseizure medications were randomized to IV ganaxolone or placebo in addition to standard of care treatment. The co-primary endpoints were the proportion of patients with status epilepticus cessation within 30 minutes and the proportion of patients not progressing to IV anesthesia within 36 hours of study drug initiation. ...Dr. Foreman continued, "With 80% of patients achieving SE cessation within 30 minutes of IV ganaxolone administration and a median time to SE cessation of 4.2 minutes, there is clear indication of rapid antiseizure activity in highly refractory patients. Although the RAISE trial did not achieve statistical significance on the second coprimary endpoint, other secondary measures of durability, such as reductions in EEG seizure burden and proportion of patients with no treatment escalation within 24 hours, showed clinically meaningful benefits."

07:04 EDT Uranium Energy receives approval to raise production capacity at Irigaray plant - Uranium Energy (UEC) announce that it has received approval from the Wyoming Department of Environmental Quality, Uranium Recovery Program, to increase the licensed production capacity at its Irigaray Central Processing Plant to 4.0 million pounds of U3O8 annually. The Irigaray Plant serves as the cornerstone of UEC's hub-and-spoke production strategy in the Powder River Basin of Wyoming. The facility supports four of UEC's fully permitted uranium in-situ recovery, or ISR, satellite projects in the area, including the producing Christensen Ranch project. Engineering work is already underway and certain key equipment, including a filter press, has been acquired to increase the plant's output. Additionally, the company announces that it has engaged Stantec (STN), of Chandler, Arizona, to provide engineering services, process design optimization, capital cost estimates, and a project execution schedule for its planned Powder River Basin production expansion. As previously announced on September 23, UEC reached a landmark deal with Rio Tinto (RIO) which will give the company a third hub-and-spoke production platform in Wyoming's Great Divide Basin. The acquisition includes the Sweetwater Plant, with a licensed capacity of 4.1M pounds of U3O8 per year, along with a portfolio of uranium projects that will add 175M pounds of historic resources to UEC's existing resource base. In addition to the two hub-and-spoke platforms in Wyoming, UEC also operates an ISR hub-and-spoke production platform in South Texas centered around the Hobson Central Processing Plant, with a licensed capacity of 4M pounds of U3O8 annually.

07:04 EDT Rockwell Automation announces Brian Hovey named Chief Marketing Officer - Rockwell Automation announced that Brian Hovey has been named vice president, Global Marketing and Chief Marketing Officer. He reports to Scott Genereux, senior vice president and Chief Revenue Officer. In his new role, Hovey has global responsibility to lead the marketing of Rockwell's full portfolio. With a focus on driving demand and building the brand globally, he oversees industry strategy, marketing communications, analyst relations, demand generation, and commercial marketing.

07:02 EDT GXO Logistics extended, expanded partnershi[p in France with Henkel - GXO Logistics announced that it has extended and expanded its partnership in France with Henkel, a multinational chemical and consumer packaged goods company. GXO manages storage, distribution, seasonal returns and value added-services for an array of Henkel brands across its laundry and homecare segments and will now expand its services to include Henkel's iconic beauty brands. "We are delighted to extend our partnership with Henkel in France," said Vincent Ricci, Managing Director, France, GXO. "Our unrivaled logistics experience and expertise will continue to optimize Henkel's operations and provide enhanced service and quality to its customers. We look forward to deploying additional technologies to further boost efficiency and enhance safety."

06:50 EDT Teleflex's Barrigel rectal spacer shows safety, efficacy in new presentation - Teleflex announced the presentation of data supporting the safety and efficacy of Barrigel rectal spacer, the first and only sculptable hyaluronic acid rectal spacer. It is designed to significantly reduce radiation that reaches the rectum during prostate cancer radiation therapy. The data were presented in three abstracta at the American Society for Radiation Oncology 2024 Annual Meeting, September 29 to October 2. Barrigel rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence of rectal wall infiltration, which can be safely reversed using hyaluronidase. Data demonstrate safety and efficacy of Barrigel rectal spacer in stereotactic body radiation therapy for patients undergoing repeat therapy. Physicians deemed Barrigel rectal spacer very easy or easy to implant. No acute or late GI toxicity greater than Grade 2 was reported; 7 acute and 5 late Grade 1 toxicity events were reported.

06:39 EDT KeyCorp reiterates long-term targets - In the long term the company expects: positive operating leverage, cash efficiency ratio of 54%-56%, net charge-offs to average loans 40-60 basis points and ROTCE 16%-19%. Guidance taken from Q3 investor presentation slides.

06:37 EDT Commercial Metals expects Q1 results to decline from Q4 level - Matt said, "We expect consolidated financial results in our first quarter of fiscal 2025 to decline from the fourth quarter level as a consequence of continued macroeconomic uncertainty and temporary, dampened sentiment within certain areas of the construction industry. Finished steel shipments within the North America Steel Group are anticipated to follow normal seasonal trends, while adjusted EBITDA margin is expected to decrease on lower steel product margin over scrap cost. Adjusted EBITDA for our Europe Steel Group should experience a meaningful sequential increase, driven by the receipt of an annual CO2 credit that is expected to be within a range of $35 million to $40 million. Underlying financial performance for the Europe Steel Group is likely to remain similar to fourth quarter levels. Financial results for the Emerging Businesses Group are anticipated to decline due to normal seasonality and the impact of economic uncertainty within the United States and Europe."

06:33 EDT Chimera to acquire Palisades Group for $30M cash at closing - Chimera Investment announced that it has entered into a definitive agreement to acquire Palisades Group, a U.S.-based alternative asset manager specializing in residential real estate credit. Founded in 2012, Palisades manages and invests in residential real estate assets across a broad spectrum of credit products. Upon closing, Jack Macdowell, Jr., co-founder and Chief Investment Officer of Palisades, will become Chimera's Chief Investment Officer. Under the terms of the agreement, Chimera will acquire Palisades for cash consideration of $30M at closing, plus an additional potential earnout of up to $20M over five years contingent upon achieving certain financial targets, with the option for Chimera to pay 50% of the earnout payments in common shares, aligning interests with those of Chimera's shareholders. Chimera expects to close the transaction during the fourth quarter of 2024, subject to the satisfaction of customary closing conditions.

06:26 EDT Parsons wins seat on $225M U.S. Army Corps of Engineers contract - Parsons was awarded a seat on a $225M multiple award task order contract by the U.S. Army Corps of Engineers Kansas City District. The contract for environmental remediation activities has a one-year base period and four one-year option periods and represents new work for the company. The contract includes projects funded by the Infrastructure Investment and Jobs Act in support of EPA cleanup projects that protect public health and safety. Under this contract, Parsons will compete for task orders to advance work assigned to USACE Northwestern Division and USEPA Region 2 at sites requiring hazardous, toxic, and radioactive waste remediation and investigation and environmental studies such as wetlands delineation, habitat mitigation, and pollution prevention.

06:21 EDT Nestle Head of SBUs Bernard Meunier to step down from Executive Board - Laurent Freixe, Nestle CEO, said: "A leaner Executive Board structure and close collaboration of the leadership team at the headquarters will increase simplicity, speed up decision-making and strengthen the momentum behind global initiatives. We will continue to build on the strengths of our Market Heads to ensure consistent in-market execution across the Group." Bernard Meunier has decided to step down from the Executive Board on March 31, 2025, and will lead strategic projects for the Group. David Rennie, currently Head of Nestle Coffee Brands will succeed Bernard Meunier as the Head of Strategic Business Units and Marketing and Sales. Nestle Coffee Brands, with the exception of Nespresso, will be integrated into the SBU organization. Nespresso is led by Philipp Navratil. He will join the Executive Board and now report directly to the Nestle CEO. Philipp Navratil is known for his ability to inspire and motivate people. He has extensive global experience across various roles and a profound understanding of Nestle. Nestle Health Science will continue to be led by Anna Mohl. Starting in 2025, Nestle's reporting will comprise five segments: Zone AMS, Zone AOA, Zone EUR, Nestle Health Science and Nespresso. The company will also continue to voluntarily report sales performance each quarter for North America and for Latin America within Zone AMS and for Greater China within Zone AOA.

06:18 EDT FTC announces final 'click-to-cancel' rule - The Federal Trade Commission on Wednesday announced a final "click-to-cancel" rule that will require sellers to make it as easy for consumers to cancel their enrollment as it was to sign up. Most of the final rule's provisions will go into effect 180 days after it is published in the Federal Register. "Too often, businesses make people jump through endless hoops just to cancel a subscription," said Commission Chair Lina M. Khan. "The FTC's rule will end these tricks and traps, saving Americans time and money. Nobody should be stuck paying for a service they no longer want." The Commission's updated rule will apply to almost all negative option programs in any media. The rule also will prohibit sellers from misrepresenting any material facts while using negative option marketing; require sellers to provide important information before obtaining consumers' billing information and charging them; and require sellers to get consumers' informed consent to the negative option features before charging them. Reference Link

06:09 EDT MSG Sports, MSG Entertainment and Sphere Entertainment enter pact with Abu Dhabi - MSG Sports (MSGS) and the Department of Culture and Tourism - Abu Dhabi announced a new marketing partnership naming 'Experience Abu Dhabi' as the Official Patch Partner of the New York Knicks, forging an integration between DCT Abu Dhabi and one of the most storied franchises in professional sports. Furthermore, MSG Entertainment (MSGE) and Sphere Entertainment (SPHR) also announced marketing partnerships with DCT Abu Dhabi, the organization driving the growth of Abu Dhabi's culture and tourism sectors and promoting the city as a global destination. These multi-year marketing partnerships will see the 'Experience Abu Dhabi' destination brand prominently integrated across premier sports and entertainment assets in the MSG Family of Companies' portfolio.

05:51 EDT Instacart names Uber's Anirban Kundu as chief technology officer - Instacart (CART) announced that Anirban Kundu will join the company as the new chief technology officer. In a blog post announcing the appointment, Instacart said: "Anirban joins us from Uber (UBER), where he was VP and Head of Engineering for Uber Delivery. At Uber, Anirban spearheaded the platform's B2B and B2C solutions, including Uber Eats and the company's Ad Solutions... At Instacart, Anirban will lead our technical team as we further expand our position as the grocery industry's leading technology company. His deep understanding of multi-sided marketplaces like ours and proven track record of building scaled technical systems that can support long-term growth make him the perfect person to drive our technical vision forward. As we continue to serve millions of customers, 600,000+ shoppers, 80,000+ stores and 6,000+ brands, we're looking forward to having Anirban's expertise and leadership to help us realize our long-term vision of building the technologies that will power every grocery transaction." Reference Link

05:40 EDT Eisai to request reconsideration of TGA decision for lecanemab in Australia - Eisai announced that the Therapeutic Goods Administration, or TGA, of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated amyloid-beta monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment, or MCI, due to Alzheimer's disease, or AD, and mild AD dementia. Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia. Following Eisai's request for review, the TGA will issue a final decision within 60 days of receiving Eisai's request. Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, Israel UAE and Great Britain, and is being marketed in the United States, Japan and China. Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and pending European approval Eisai and BioArctic are preparing for a joint commercialization in the region.

05:31 EDT Nokia backs FY24 comparable operating profit view EUR 2.3B-EUR 2.9B - Backs FY24 free cash flow view 30%-60% conversion from comparable operating profit. The company said, "Regarding our financial performance in Q3, our net sales declined by 7% in the quarter in constant currency. Three quarters of the decline was driven by India due to a strong year-ago quarter. Importantly we delivered a significant improvement in comparable gross margin which expanded 490 basis points from the year-ago period to reach 45.7%. This was driven by a combination of improved product mix, regional mix and actions to reduce product cost. Despite continued intense competition, we remain disciplined on price while still winning deals as we remain focused on improving the profitability of our business. We also progressed our cost reduction efforts contributing to a solid improvement of 160 basis points in our comparable operating margin on a year-on-year basis. Regarding full year 2024, our comparable operating profit outlook remains EUR 2.3 to 2.9 billion and we are currently tracking within the bottom-half of the range. The net sales recovery is happening slower than we expected previously, however, this is being partially offset by an improving gross margin and quick action on cost. We expect to be at the high end of our free cash flow target of 30% to 60% conversion from comparable operating profit."

05:14 EDT Travere reports Swissmedic grants temporary marketing authorization for Filspari - CSL Vifor and Travere Therapeutics announced that Swissmedic has granted temporary marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy, or IgAN, with a urine protein excretion of one g/day. Swissmedic approval was supported by results from the pivotal phase-III PROTECT study of Filspari in IgAN and follows full marketing approval by the FDA in September and conditional marketing authorization by the European Medicines Agency in April.

05:06 EDT Tuniu regains compliance with Nasdaq - Tuniu announced that it has received a notification letter from Nasdaq informing the company that it has regained compliance with the Nasdaq Listing Rule 5450(a)(1).